Hefny 2018.
Study characteristics | ||
Methods | Placebo‐controlled double‐blind randomised clinical trial | |
Participants | Infertile women attending an Obstetrics and Gynaecology clinic. Women with PCOS undergoing timed intercourse (Mean age = ?) (N = 200) Inclusion criteria: PCOS infertile women Exclusion criteria: Unknown |
|
Interventions | 1. Clomiphene citrate 100 mg/day plus NAC 1.2 g/day (N = ?)) 2. Clomiphene citrate 100 mg/day plus placebo (N = ?) Treatment for 5 days starting at day 3 of the cycle |
|
Outcomes | The number of follicles > 18 mm on the day of hCG administration Ovulation rates The mean endometrial thickness Pregnancy No adverse side‐effects and no cases of OHSS were observed in the group receiving NAC |
|
Notes | Conference abstract Location: Obstetrics and Gynaecology, El Hussein University Hospital, Cairo, Egypt Timeframe: Unkown Trial registration number: Unkown Informed consent: Unkown Ethical approval: Unkown Sample size power calculation: Unkown Funding: Unkown Conflict of interests:Unkown ITT: Unkown Author email: Unkown and unable to find |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Quote: "Randomly divided" |
Allocation concealment (selection bias) | Unclear risk | Unknown |
Blinding (performance bias and detection bias) All outcomes | Low risk | Quote: "Placebo‐controlled double‐blind" |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Unknown |
Selective reporting (reporting bias) | Unclear risk | Trial registration number not available |
Other bias | Unclear risk | Conference abstract ‐ baseline characteristics unclear |